Buy pharmaceutical chemicals online | pharmaceutical chemicals manufacturers | pharmaceutical chemicals suppliers - Worldofchemicals

chemical-categories

Orantinib

Orantinib is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. Orantinib also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.

Properties Suppliers
Orazamide

Orazamide a salt of aminoimidazole carboxamide has been used as a hepatoprotectant based on its ability to prevent necrosis and stimulate regeneration of the liver parenchymal cells.

Properties Suppliers
Ortataxel

Ortataxel is a drug used in chemotherapy.

Properties
Osanetant

Osanetant is a neurokinin 3 receptor antagonist developed by Sanofi-Synthélabo, which is being researched for the treatment of schizophrenia. It was the first non-peptide NK3 antagonist developed in the mid-1990s, and has still not made it to market, although clinical trials are continuing. Another potential application for osanetant is in the treatment of drug addiction, as it has been found to block the effects of cocaine in animal models.

Properties
Otenabant

Otenabant is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesity, but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.

Properties Suppliers
Oxolamine

Oxolamine is a cough suppressant.

Properties
PD0325901

PD0325901 is a MEK inhibitor, is an orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity.

Properties Suppliers
PNU-22394

PNU-22394 is a drug which acts as an agonist at serotonin 5-HT2 receptors, with strongest binding affinity for 5-HT2A and 5-HT2C and slightly weaker at 5-HT2B, although it is only a full agonist at 5-HT2C, but partial agonist at 5-HT2A and 5-HT2B. It has anorectic effects in both animal studies and human trials, although it has never been developed for medical use.

Properties
Pagoclone

Pagoclone is an anxiolytic drug from the cyclopyrrolone family, related to better-known drugs such as the sleeping medication zopiclone. It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures. It was originally developed as an anti-anxiety drug, but never commercialised. It is a partial agonist acting at GABAA receptors in the brain. In contrast to zopiclone, pagoclone produces anxiolytic effects with little or no sedative or amnestic actions at low doses. This is because pagoclone is a subtype-selective drug which binds primarily to the α2 and α3 subtypes of the GABAA receptor which are responsible for the anti-anxiety effects of these kind of drugs, but has relatively little efficacy at the α1 subtype which produces the sedative and memory loss effects.

Properties
Pargyline

Pargyline is an irreversible monoamine oxidase B inhibitor. It has antihypertensive effects. It functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Patients taking pargyline must avoid concurrent consumption of tyramine-containing foods such as blue cheese and beer, as this can lead to a hypertensive crisis.

Properties

www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X